Fundraising Fox
Windward Bio
48 employees on LinkedIn · 10 known investors
Find your way into Windward Bio
Sign up to see every warm intro you have to Windward Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Windward Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases. Its lead program WIN378 is an ultra long-acting anti-TSLP antibody in a Phase 2/3 asthma trial and Phase 2 COPD study, with a broader pipeline including the anti-TSLPxIL-13 bispecific WIN027.
Investors · 10
How we know: OrbiMed's portfolio page · a partner's Signal profile · funding news · the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: RA Capital's portfolio page · funding news · Not right? Tell us
How we know: Sanofi Ventures's portfolio page · funding news · Not right? Tell us
How we know: SR One Capital Management's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$165M disclosed across 1 of 3 rounds · 2025–2026
- $165MCrossoverMay 2026Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Windward Bio do?
- Windward Bio is a clinical-stage biotechnology company developing long-acting monoclonal and bispecific antibodies for serious immunological conditions such as asthma, COPD, and dermatological diseases. Its lead program WIN378 is an ultra long-acting anti-TSLP antibody in a Phase 2/3 asthma trial and Phase 2 COPD study, with a broader pipeline including the anti-TSLPxIL-13 bispecific WIN027.
- Who are Windward Bio's investors?
- Windward Bio's investors include OrbiMed, Quan Capital, RA Capital, Sanofi Ventures, SR One Capital Management, Janus Henderson Investors, Novo Holdings, Pivotal Life Sciences and 2 more.
- How much funding has Windward Bio raised?
- Windward Bio has disclosed $165M raised across 1 of its 3 known rounds.